EconPapers    
Economics at your fingertips  
 

Revolving drug funds: Conducting business in the public sector

Peter N. Cross, Maggie A. Huff, Jonathan D. Quick and James A. Bates

Social Science & Medicine, 1986, vol. 22, issue 3, 335-343

Abstract: Pharmaceuticals are essential for preventive and therapeutic health services. Unfortunately, significant demand, limited funds and high prices contribute to frequent shortages of drugs in many public health programs. One method for financing pharmaceutical supplies has been the establishment of revolving drug funds (RDFs) in which, after an initial capital investment, drug supplies are replenished with monies collected from the sale of drugs. All too often however, the funds actually recovered are insufficient to replenish supplies and the fund is soon depleted. In this paper we consider the potential benefits and common pitfalls of revolving drug funds and then focus on the central role of financial planning in establishing drug sales programs. Experiences from a variety of countries suggest several causes for the failure of some RDFs, including: (1) under-estimation of capitalization costs, (2) prices set below true replacement cost, frequent failure to collect payment, (3) delays in cash flow which make funds unavailable for replenishment of drug stocks, (4) rapid program expansion for which additional capital funds are not available, (5) losses due to theft and deterioration of drugs, (6) unanticipated price increases due to inflation or changes in parity rates and (7) foreign exchange purchase restrictions. Common to many of these problems is the lack of a businesslike orientation to RDFs and, in particular, lack of careful financial planning and management. Financial planning for an RDF includes four analytical tasks: 1. (1) assessment of the potential market, 2. (2) estimation of the costs of an RDF, 3. (3) establishment of the cost-recovery objectives, 4. (4) definition of the role of subsidies and surcharges. Revolving drug funds offer great potential for supplying drugs in many parts of the Third World, but they must be carefully planned and the organizers should bear in mind the pitfalls which commonly undermine these programs.

Date: 1986
References: Add references at CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/0277-9536(86)90132-2
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:socmed:v:22:y:1986:i:3:p:335-343

Ordering information: This journal article can be ordered from
http://www.elsevier.com/wps/find/supportfaq.cws_home/regional
http://www.elsevier. ... _01_ooc_1&version=01

Access Statistics for this article

Social Science & Medicine is currently edited by Ichiro (I.) Kawachi and S.V. (S.V.) Subramanian

More articles in Social Science & Medicine from Elsevier
Bibliographic data for series maintained by Catherine Liu ().

 
Page updated 2025-03-19
Handle: RePEc:eee:socmed:v:22:y:1986:i:3:p:335-343